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Borrelia burgdorferi evades complement-mediated killing by interacting with complement regulators through distinct complement
regulator-acquiring surface proteins (CRASPs). Here, we extend our analyses to the contribution of CRASP-4 in mediating
complement resistance of B. burgdorferi and its interaction with human complement regulators. CRASP-4 (also known as ErpC)
was immobilized onto magnetic beads and used to capture proteins from human serum. Following Western blotting, factor H
(CFH), CFH-related protein 1 (CFHR1), CFHR2, and CFHR5 were identified as ligands of CRASP-4. To analyze the impact of
native CRASP-4 on mediating survival of serum-sensitive cells in human serum, a B. garinii strain was generated that ectopically
expresses CRASP-4. CRASP-4-producing bacteria bound CFHR1, CFHR2, and CFHR5 but not CFH. In addition, transformed
spirochetes deposited significant amounts of lethal complement components on their surface and were susceptible to human
serum, thus indicating that CRASP-4 plays a subordinate role in complement resistance of B. burgdorferi.
1. Introduction
Lyme borreliosis, caused by spirochetes of the Borrelia burg-
dorferi sensu lato complex, is the most prevalent vector-
borne anthropozoonosis in Eurasia and the United States
[1]. The ability of spirochetes to perpetuate their natural
vertebrate-tick infectious cycle spirochetes requires an array
of mechanisms to successfully colonize their tick vectors
and rodent reservoir hosts, survive in diverse environments,
and evade host innate and adaptive immune responses. Re-
cently, it has been shown that certain genospecies resist
complement-mediated killing of human serum, in particular
B. burgdorferi sensu stricto (hereafter referred to as B.
burgdorferi), B. afzelii, B. spielmanii, and B. bavariensis (for-
merly known as B. garinii OspA serotype 4 strains) [2–
5]. Elucidation of the underlying molecular mechanism(s)
of complement resistance among Lyme disease spirochetes
revealed that binding of the host complement regulators
factor H (CFH) and factor H-like protein 1 (FHL1) to the
bacterial surface directly correlates with serum resistance [3,
6–10]. In contrast, B. garinii, B. valaisiana, and B. lusitaniae
are highly susceptible to complement-mediated killing and
either do not bind, or bind inadequate levels of complement
regulators [2, 4, 10–12].
Complement plays a central role in the recognition
and elimination of invading microorganisms [13]. Upon
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activation of the initial steps of the complement cascade via
the classical, alternative, or lectin pathway, a C3 convertase
is generated which cleaves the central component C3 into
its reactive fragments C3a and C3b. The highly reactive C3b
fragment covalently binds to molecules, proteins, and nearby
membranes, thereby leading to opsonization of the intruding
microorganisms. This initial step is necessary for clearance
of foreign microorganisms by phagocytosis, formation of
the C3 convertase, and assembly of both the C5 convertase
and the membrane attack complex (MAC). To protect host
cell surfaces from uncontrolled and continuous activation,
the complement system is well balanced and finely tuned by
diverse fluid phase and membrane-anchored negative regu-
lators [14–16]. CFH and FHL1 are the key fluid phase regula-
tors of the human alternative pathway and act as cofactors for
factor-I-mediated inactivation of C3b to iC3b, compete with
factor B for binding to C3b, and finally support the dissoci-
ation (decay-accelerating activity) of the alternative pathway
C3 convertase, C3bBb [16–20]. CFH is composed of 20
individually folding protein domains termed short consensus
repeats (SCRs) of which the four N-terminal-located SCRs
exhibit the complement regulatory activity. FHL1 is a 42 kDa
glycoprotein, comprised of the seven amino-terminal SCRs
of CFH plus four unique amino acids at the C-terminus [17,
20]. The human CFH family includes additional “factor H-
related” proteins (CFHR), namely, CFHR1, CFHR2, CFHR3,
CFHR4A, CFHR4B and CFHR5, all of which are encoded
by distinct genes located in the regulators of complement
activation (RCA) gene cluster on human chromosome 1
[21–23]. The C-terminal SCR domains of the CFHR proteins
share high degrees of similarity to the C-terminal surface
binding region of CFH, that is, SCRs 18–20 [16, 24]. The
CFHR1 protein consists of five SCRs and exists in two gly-
cosylated forms, the 37 kDa CFHR1α protein with one and
the 43 kDa CFHR1β protein with two carbohydrate chains
attached [25, 26]. CFHR1 is a complement regulator that
blocks C5 convertase activity as well as assembly and mem-
brane insertion of the terminal membrane attack complex
[27]. CFHR2 is composed of four SCRs and is found in
plasma as a nonglycosylated 24 kDa form (CFHR2) and a
glycosylated 29 kDa form (CFHR2α) [28]. The function(s)
of CFHR2 is as still unclear. The 65 kDa CFHR5 protein
is comprised of 9 SCRs and displays cofactor activity for
factor-I-mediated inactivation of C3b [29, 30]. CFHR5 also
inhibits the activity of the fluid phase C3 convertase.
Lyme disease Borreliae camouflage themselves with host-
derived complement regulators through three groups of ge-
netically unrelated genes/proteins collectively termed com-
plement regulator-acquiring surface proteins or “CRASPs”
[3, 9, 31–35]. All investigated serum-resistant borrelial
strains so far express the CRASP-1 protein in different com-
binations with CRASP-2, CRASP-3, CRASP-4, and/or
CRASP-5. Based on the binding profile for complement reg-
ulators, CRASPs expressed by B. burgdorferi are divided into
CFH and FHL1 binding proteins that do not bind CFHR1
(CRASP-1/CspA and CRASP-2/CspZ) and molecules that
interact with CFH and CFHRs, but not FHL1 (CRASP-
3/ErpP, and CRASP-4/ErpC, CRASP-5/ErpA) [9, 34, 36–
39]. The potential of single CRASP-molecules in mediating
complement resistance of B. burgdorferi s.s. is still under
debate. Borrelial strains lacking functional CRASP-1 and
CRASP-2 are highly susceptible to complement-mediated
killing, and complementation with the respective CRASP
encoding genes restores the serum-resistant phenotype [31,
40–42]. The contributions of the CFH and CFHR-binding
CRASP-3 and CRASP-5 proteins in facilitating complement
resistance of Borreliae are disputed. Heterologous production
of either CRASP-3 or CRASP-5 in a B. garinii strain lacking
all functional CRASP molecules failed to convert the serum-
sensitive phenotype of the wild-type strain [39]. In contrast,
Kenedy and Akins have shown that CRASP-3 and CRASP-
5 produced in a CRASP-1 deletion strain lead to increased
survival in human serum as compared to a serum-sensitive
strain lacking CRASP-1 [43].
In the present studies, we extended our previous inves-
tigations on the CFH- and CFHR1 binding capacity of
CRASP-4/ErpC protein to additional proteins derived from
human serum and their contributions to convey complement
resistance. To this end, a B. garinii strain that ectopically
produced CRASP-4 was generated by transformation with a
shuttle vector harboring the CRASP-4 encoding erpC gene,
then the transformed strain was assayed for (i) the ability to
bind human complement regulators, (ii) surface deposition
of complement activation products, and (iii) survival in
human serum. Using recombinant CRASP-4, two additional
members of the human CFH protein family, CFHR2 and
CFHR5, were identified as novel ligands for CRASP-4 of B.
burgdorferi whereby CFHR2 showed stronger binding ca-
pacity for CRASP-4 as compared to CFHR1 and CFHR5.
However, borrelial cells producing CRASP-4 on their surface
did not bind CFH. Upon incubation in human serum,
large amounts of activated complement components were
deposited onto the surfaces of CRASP-4 producing cells and
the bacteria did not survive. This suggests that binding of
CFHR1, CFHR2, and CFHR5 is not sufficient to protect
spirochetes from complement-mediated bacteriolysis once
complement is activated.
2. Material and Methods
2.1. Bacterial Strains and Culture Conditions. B. burgdorferi
strains LW2 (skin isolate, Germany), B. garinii isolate G1
(CSF isolate, Germany), B. garinii transformants G1/pKFSS1
as well as G1/pCRASP-4 were grown at 33◦C for 2 to 4 days
to midexponential phase (1× 107 to 5× 107 spirochetes/mL)
as described previously [39]. Escherichia coli DH5α used
for cloning experiments and protein expression was grown
at 37◦C in yeast tryptone broth, supplemented with the
appropriate antibiotics.
2.2. Human Sera and Polyclonal and Monoclonal Antibodies.
Normal human serum (NHS) obtained from 20 healthy
human blood donors without known history of spirochetal
infections was used as a source of complement regulators.
The study and the respective consent documents were
approved by the ethics committee at the Goethe University
of Frankfurt (control number 160/10). All blood donors pro-
vided written, informed consent.
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Table 1: Oligonucleotides used in this study.
Oligonucleotide Sequence (5′–3′)a Use in this work
ErpC 5nc(+)
GTTGTATGTGTTTTGAAGCTTTTAGTAATGAGCAGGGC Cloning in pKFSS1 and amplification of erpC
HindIII
ErpC 3nc(−)
CGATCTCTCCTGTATTTTAAGCTTCTATTTTAAATTTTTCTTAAG Cloning in pKFSS1 and amplification of of erpC
HindIII
aadA + NdeI CATATGAGGGAAGCGGTGATC Amplification of aadA gene
aadR + AatII GACGTCATTATTTGCCGACTACC Amplification of aadA gene
Fla6 AACACACCAGCATCGCTTTCAGGGTCT Amplification of flaB gene
Fla7 TATAGATTCAAGTCTATTTTGGAAAGCACCTA Amplification of flaB gene
aSequences of specific restriction endonuclease recognition sites are underlined.
A polyclonal anti-CFH antiserum was utilized to detect
human CFH, CFHR1, and CFHR2 (Merck Biosciences,
Bad Soden, Germany and Complement Technology, Tyler,
TE). Rabbit polyclonal anti-CFHR1 antibody or monoclonal
antibody JHD 7.10 was used for detection of CFHR1 and
CFHR2 and CFHR5 [39]. The goat anti-human C3 and C6
antibodies were purchased from Calbiochem, and the mono-
clonal anti-human C5b-9 antibody recognizing the MAC was
obtained from Quidel (San Diego, CA). MAb L41 1C11 was
used to detect the periplasmic FlaB protein. For analyzing
surface-exposed CRASP-4, a rabbit polyclonal antiserum that
recognizes CRASP-4 and CRASP-5 was used [44, 45].
2.3. Expression of Recombinant CFHR1, CFHR2, and CFHR5.
Recombinant CFHR1 was expressed in Spodoptera frugiperda
Sf9 insect cells infected with recombinant baculovirus. The
cloning of various deletion constructs, expression, and
purification have been described previously [38].
The full length CFHR2 cDNA was cloned into pPICZαB
(Invitrogen), and the protein was expressed in the yeast
Pichia pastoris strain X33 according to standard protocols
[39]. The full length CFHR5 cDNA was cloned into pBSV-
8His and expressed in the baculovirus system as described
[46]. All expressed His-tagged recombinant proteins were
purified by Ni2+ chelate affinity chromatography as described
[46].
2.4. Expression of Recombinant CRASP-4. The construction
of vector pBLS528 used for the production of amino-ter-
minally polyhistidine-tagged CRASP-4 (ErpC) was described
previously [47]. The erpC encoding sequence of B. burgdor-
feri strain LW2 is identical to the sequence of the erpC gene
of B. burgdorferi type strain B31.
Expression of recombinant CRASP-4 protein was in-
duced in DH5α at an OD600 of 0.6 by the addition of
0.2 mM IPTG. Following incubation for 4 h at room tem-
perature, cells were centrifuged (5000 g, 20 min, 4◦C) and
subsequently suspended in lysis buffer (300 mM NaCl,
56 mM NaH2PO4 pH 8, and 10 mM Imidazole) containing
50 mg/mL lysozyme. Bacterial cells were lysed by 6 rounds of
sonication for 30 sec using a Branson B-12 sonifier (Heine-
mann, Schwäbisch Gmünd, Germany). After centrifugation
(14000 g, 20 min, 4◦C), supernatants were filtered through
0,45 μm filters and stored at −20◦C for later purification via
affinity chromatography.
2.5. Serum Incubation with Magnetic Beads Coated with
His-Tagged CRASP-4 Protein. Purified CRASP-4 (20 μg) was
incubated with 50 μL of magnetic beads (Dynabeads TALON,
Invitrogen Dynal AS, Oslo, Norway) for 10 min at room
temperature as recommended by the manufacturer. After
four wash steps with phosphate buffer (50 mM phosphate,
300 mM NaCl, 0.01% Tween 20), histidine-tagged proteins
coupled onto beads were incubated with NHS for 1 h on
ice. After extensive washing with phosphate buffer, bound
proteins were eluted with 50 μL of 100 mM glycine-HCl
(pH 2.0) for 15 min. The eluate and the last wash fraction
were separated by 12.5% SDS-PAGE under nonreducing
conditions followed by silver staining.
2.6. Construction of Shuttle Vectors. To allow ectopic expres-
sion of CRASP-4 by the serum-sensitive B. garinii strain G1,
a shuttle vector was generated by using plasmid pKFSS1,
a streptomycin-resistant derivative of pBSV2 [48]. The
CRASP-4 encoding erpC gene plus its native promotor region
was amplified from B. burgdorferi strain LW2 by PCR using
primers containing the respective restriction sites and then
sequenced (Table 1). The sequence of the erpC gene of B.
burgdorferi strain LW2 is identical to that of B. burgdorferi
type strain B31. Amplicons were hydrolyzed with HindIII
and subsequently cloned into pKFSS1 at the corresponding
restriction site, yielding shuttle vector pCRASP-4. The
inserted sequence was subjected to nucleotide sequencing to
verify that no mutations had been introduced during PCR
and cloning procedures.
2.7. Transformation of Serum-Sensitive B. garinii. The non-
infectious, serum-sensitive B. garinii strain G1 was grown
in BSK medium and harvested at midexponential phase (5
× 107 to 1 × 108 cells/mL). Electrocompetent cells were
prepared and transformed as described previously [39]. For
selection of transformants, cells were diluted into 100 ml BSK
medium containing 20 μg/mL streptomycin, then 200 μL
aliquots were transferred into 96-well plates (Corning). After
four to six weeks of incubation at 33◦C, wells were evaluated
for growth by color change of the medium and by dark-field
microscopy for the presence of motile spirochetes. Several
clones were expanded in 1 mL fresh BSK medium containing
streptomycin (20 μg/mL) for 7 to 14 days. Transformed
bacteria were then maintained in BSK medium containing
20 μg/mL streptomycin.
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2.8. PCR Analysis of Transformed Borrelial Cells. Strepto-
mycin-resistant clones of transformed B. garinii were char-
acterized by PCR amplification of the introduced erpC gene
and the recombinant plasmids streptomycin resistance gene
(aadA) using specific primers (Table 1). The native B. garinii
flaB gene was also amplified via PCR as a positive control. Ten
microliter aliquots of bacterial cultures grown to midexpo-
nential phase were used for direct PCR. PCR was carried out
for 25 cycles using the following parameters: denaturation at
94◦C for 1 min, annealing at 50◦C for 1 min, and extension at
72◦C for 1 min. Reaction products were separated by agarose
gel electrophoresis, and DNA was visualized by ethidium
bromide staining and ultraviolet light.
2.9. SDS-PAGE, Western Blot, and Ligand Affinity Blot Analy-
sis. Bacterial cell lysates were subjected to 10% Tris/Tricine-
SDS-PAGE under reducing conditions and samples obtained
by serum adsorption (last wash and eluate fractions) were
separated by SDS-PAGE under nonreducing conditions as
previously described [34].
For ligand affinity blot analysis, membranes were incu-
bated for 1 h with normal human serum. After four wash-
ings with TBS containing 0,2% Tween20, membranes were
incubated for 1 h with either a polyclonal goat CFH anti-
serum, polyclonal anti-CFHR1 antiserum that recognizes
CFHR1, CFHR2, and CFHR5 and CFH or mAb JHD 7.10
which recognizes all three CFHRs but not CFH [38, 39, 49].
Following four washings with TBS containing 0,2% Tween
20, membranes were incubated with an appropriate perox-
idase-conjugated secondary antibody for 1 h. Detection of
bound proteins was performed using 3, 3′, 5, 5′-tetrameth-
ylbenzidine (TMB) as a substrate.
For Western blot analysis, membranes were incubated for
1 h at room temperature with antisera recognizing CRASP-
4/ErpC and CRASP-5/ErpA (αCRASP-4), CFH, CFHR1,
or FlaB (L41 1C11). Following four wash steps with
TBS containing 0,2% Tween20, membranes were probed
with appropriate peroxidase-conjugated secondary antisera
(Dako, Glostrup, Denmark) for 60 min at room temperature
and bound antibodies were detected using TMB.
2.10. ELISA. Microtiter plates (Nunc-Immuno Module)
were coated with CRASP-4 (5 μg/mL) over night at 4◦C. Mic-
rotiter plates were washed with PBS containing 0.1% Tween
20 and treated for 1 h at RT with blocking buffer (AppliChem
GmBH, Darmstadt, Germany). After washing, equimolar
amounts (33 μM) of CFH, CFHR1, CFHR2, or CFHR5 were
added and incubated for 1 h at RT. Thereafter, the wells were
washed and bound CFH or CFHR proteins were detected
with either goat CFH polyclonal antiserum or MAb JHD
7.10, which reacts with all three CFHRs [39, 49]. After wash-
ing, bound proteins were identified using appropriate sec-
ondary horseradish peroxidise-coupled antisera. Detection
was performed with 1,2-phenylenediamine dihydrochloride
as a substrate (OPD, DakoCytomation, Glostrup, Denmark)
and absorbance was measured at 490 nm.
2.11. In Situ Protease Accessibility Experiments. Viable Bor-
reliae were gently washed and resuspended in 500 μL PBS
to obtain a density of 8 × 105/μL. Subsequently, proteinase
K and trypsin (Sigma-Aldrich, Deisenhofen, Germany)
were separately added to a final concentration of 25 and
100 μg/mL, respectively. Intact spirochetes without protease
treatment served as a control. Following incubation for
2 h at room temperature, proteinase K and trypsin were
inactivated by addition of phenylmethylsulfonyl fluoride
(Sigma-Aldrich) (50 mg/mL in isopropanol). Cells were then
washed gently twice with PBS-5 mM MgCl, resuspended
in 20 μL of the same buffer, then lysed by sonication 5
times for 30 sec using a Branson B-12 sonifier (Heinemann,
Schwäbisch Gmünd, Germany). Aliquots were separated us-
ing Tris/Tricine-SDS-PAGE as described above.
2.12. Serum Adsorption Assay. To assess binding of serum
proteins to viable borrelial cells, a serum adsorption assay
was employed as described previously [7, 50]. Briefly,
borrelial cells (1 × 109 cells) grown to midexponential
phase were washed and subsequently resuspended in 750 μL
NHS supplemented with 34 mM EDTA (pH 8.0) to avoid
complement activation. After 1 h incubation and four washes
with PBS containing 0.01% Tween 20, proteins bound to the
cells surface were eluted with 100 mM glycine-HCl (pH 2.0)
for 15 min. Cells were removed by centrifugation at 14000 g
for 10 min at 4◦C, and the supernatant and the last wash were
separated by SDS-PAGE under nonreducing conditions and
analyzed by Western blotting as described above.
2.13. Serum Susceptibility Testing. Serum susceptibility of
B. garinii isolate G1, G1/pKFSS1, and G1/pCRASP-4 was
assessed by a growth inhibition assay as described previously
[3, 42]. Briefly, aliquots (1.25 × 107 cells) of highly motile
spirochetes were diluted into final volumes of 100 μL fresh
BSK medium, which contains 240 μg/mL phenol red. As
bacteria grow in BSK, the medium acidifies and the pH
indicator dye turns from red to yellow. One hundred micro-
liters of NHS or 100 μL heat-inactivated NHS was added
to each aliquot of bacteria. Bacteria were then incubated in
96-well microtiter plates for 8 days at 33◦C. For controls,
aliquots of bacteria were also incubated with 100 μL BSK
medium instead of NHS. Bacterial growth was monitored
daily by measuring the ratio of culture medium absorbance
at 562 versus 630 nm, using an ELISA reader (PowerWave
HT; Bio-Tek Instruments, Winooski, VT). For calculation of
the growth curves the Gen5 software (Bio-Tek Instruments,
Winooski, VT) was used. Each experiment was conducted at
least three times, and means ± SD were calculated.
2.14. Immunofluorescence Assay. Spirochetes grown to mid-
exponential phase were harvested by centrifugation (5000 g,
30 min), washed, and resuspended in veronal buffered saline
(VBS, supplemented with 1 mM Mg2+, 0.15 mM Ca2+, and
0.1% gelatin, pH 7.4).
For detection of deposited complement components on
the bacterial surface, spirochetes (6 × 106) were incubated in
25% NHS and, as a control, in 25% heat-inactivated NHS for
30 min at 37◦C with gentle agitation as previously described
[3, 42].
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Figure 1: Identification of serum proteins that bind to recombinant CRASP-4. Recombinant, polyhistidine-tagged CRASP-4 was immo-
bilized onto magnetic beads and incubated with NHS. Uncoated beads were also treated under the same conditions and used as a control to
identify nonspecific binding of serum proteins. After extensive washing, bound proteins were eluted with 100mM glycine-HCl (pH 2.0) and
the eluate fractions were separated by SDS-PAGE under nonreducing conditions. (a) Silver stain of a gel loaded with purified polyhistidine-
tagged CRASP-4 (1 μg), eluate fraction of the uncoated beads, and the final wash and eluate fraction of CRASP-4-coated beads. (b) Western
blot analysis of the eluate fraction of CRASP-4-coated beads using a polyclonal anti-CFH or a polyclonal anti-CFHR1 antiserum. Mobilities
of molecular mass standards are indicated to the left.
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Figure 2: CRASP-4 binds distinct complement proteins. Binding of
equimolar amounts of CFH, CFHR1, CFHR2, and CFHR5 (33 μM)
to immobilized CRASP-4 (5 μg/mL) was analyzed by ELISA. Bound
CFH or CFHR proteins were detected with either goat CFH
polyclonal antiserum or mouse CFHR1 monoclonal antiserum
(JHD 7.10), which reacts with all three CFHRs. Data represent the
means and standard errors from three separate experiments.
In order to detect surface-exposed proteins, polyclonal
rabbit anti-CRASP-4 antiserum (1:50 dilution) was added
to the cells for 1h at 37◦C with gentle agitation. After two
washes with PBS containing 1% BSA, 10 μL aliquots of the
cell suspensions were spotted on glass slides and allowed to
air-dry overnight (= unfixed cells). Slides were then fixed
in methanol for 10 min and air-dried for 1 h, followed by
incubation with an adequate Alexa 488-conjugated antibody.
Slides were then gently washed four times with PBS and
mounted on ProLong Gold antifade reagent (Molecular
Probes) containing DAPI before being sealed. Slides were
visualized at a magnification of ×1,000 using an Olympus
CX40 fluorescence microscope mounted with a DS-5Mc
charge-coupled device camera (Nikon).
As a control, periplasmic FlaB was also investigated using
unfixed as well as fixed spirochetes as described previously
[39].
3. Results
3.1. CRASP-4 Interacts with Human Complement Regulators.
To identify serum components that bind to CRASP-4, the
purified his-tagged protein was immobilized on magnetic
beads. Following incubation with NHS, beads were exten-
sively washed and bound serum proteins along with CRASP-
4 were eluted. The eluate fraction of the CRASP-4-coated
beads and eluate fraction of uncoated beads as well as the
final wash were separated by SDS-PAGE and analyzed by
silver staining (Figure 1(a)). A bulk of proteins in the 60 to
80 kDa range was detected in the eluate fractions of CRASP-
4-coated beads and also in the eluate fraction of uncoated
beads. In the eluate fraction of uncoated beads and in the
final wash fraction but not in the eluate fraction of CRASP-
4-coated beads, a 55 kDa protein was found. In contrast,
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proteins with apparent molecular masses of 60, 38, 35,
29, 25 and 22 kDa were detected only in the eluate fraction
of CRASP-4-coated beads.
To identify the serum proteins bound to the recombinant
CRASP-4 protein, Western blot analysis was performed using
specific antisera. All serum proteins bound to CRASP-4 react
with the polyclonal anti-CFHR1 antiserum that recognizes
the two different glycosylated forms of CFHR1 (CFHR1α
and CFHR1β) and CFHR2 (CFHR2, and CFHR2α) as well
as CFHR5 (Figure 1(b)). By using a polyclonal anti-CFH
antiserum, four signals corresponding to CFHR1α (35 kDa)
and CFHR1β (32 kDa) and CFHR2 (25 kDa) and CFHR2α
(22 kDa) could be detected. The 150 kDa CFH protein
was not detected by either silver staining or Western blot,
indicating that CRASP-4 did not bind CFH under these
experimental conditions. The protein with an apparent mass
of 22 kDa represents CRASP-4. Taken together, CRASP-4
binds to human CFH protein family members, including
CFHR1, CFHR2, and CFHR5.
Next, binding of recombinant CRASP-4 to each of the
three identified human serum proteins was analyzed by ELI-
SA (Figure 2). CRASP-4 was immobilized onto a microtiter
plate and binding of purified recombinant CFHR1, CFHR2,
CFHR5 and serum-purified CFH was assayed. All three
CFHR proteins, that is, CFHR1, CFHR2, and CFHR5 as well
as CFH bound to the immobilized CRASP-4 protein, with
the greatest apparent affinity being for CFHR2.
3.2. Generation of a CRASP-4-Expressing B. garinii Strain.
Depending on the genetic composition, all serum-resistant B.
burgdorferi isolates analyzed to date express at least two dis-
tinct CRASP molecules. In order to assess the contribution
of an individual CRASP molecule in mediating complement
resistance, the serum-sensitive B. garinii strain G1 (does
not express any of these CRASP proteins during laboratory
cultivation) was chosen for functional analyses of the
CRASP-4 protein [34]. B. garinii G1 was transformed with
the plasmid pCRASP-4, which harbors the entire CRASP-4
encoding erpC gene under the control of its native promotor,
and with the empty shuttle vector pKFSS1. Transformants
selected by the microdilution method were confirmed by
PCR amplification of the CRASP-4 encoding erpC and
the streptomycin resistance aadA gene (Figure 3(a)). Strain
G1/pCRASP-4 yielded an amplicon corresponding to erpC,
whereas the control strains G1 and G1/pKFSS1 did not.
The aadA gene of the shuttle vectors was detected in
the transformed cells, but not in the wild-type strain G1.
Production of CRASP-4 in B. garinii G1 was verified through
analysis of cell lysates from the CRASP-4 expressing cells
and the nonexpressing control strains G1 and G1/pKFSS1
(Figure 3(b)).
3.3. Surface Exposure of CRASP-4 in B. garinii G1/pCRASP-4.
CRASP-4 and other members of the Erp paralogous protein
family are surface exposed proteins [44]. To confirm surface-
exposure of these proteins in transformed B. garinii, intact
spirochetes were treated with proteinase K and trypsin,
followed by ligand affinity blotting of borrelial lysates
(Figure 3(c)). Analyses of protease-treated cells revealed that
CRASP-4 was highly susceptible to digestion by proteinase K
but not trypsin, as previously described for the native protein
[44]. Surface localization of CRASP-4 was also examined
by immunofluorescence microscopy using live bacteria and
polyclonal antibodies specific for CRASP-4 [44]. To avoid
damage to the fragile borrelial outer membrane, intact
bacteria were incubated with antibodies before fixation onto
glass slides and sealed with mounting medium containing
the DNA-binding dye DAPI. As shown in Figure 3(d),
CRASP-4 positive cells showed a strong fluorescent staining,
thus indicating that CRASP-4 was localized on the outer
membrane. Integrity of the fragile borrelial outer membrane
was confirmed by the lack of binding of antibodies directed
against the periplasmic flagellar protein FlaB (Figure 3(d)).
Control strains G1 or G1/pKFSS1 did not display fluores-
cence reactivity with the CRASP-4 antiserum.
3.4. Binding of Human Serum Proteins by B. garinii
G1/pCRASP-4. Having demonstrated binding of CFHR1,
CFHR2 and CFHR5 to recombinant CRASP-4, we next ex-
amined whether live G1/pCRASP-4 cells also bind the human
complement regulators. To this end, serum-resistant B.
burgdorferi LW2 (positive control), serum-sensitive B. garinii
G1 (negative control), and transformants G1/pKFSS1 and
G1/pCRASP-4 were incubated in NHS supplemented with
EDTA (to prevent complement activation). After serum
incubation, the final wash and elute fractions were separated
by SDS-PAGE and subjected to Western blotting with a poly-
clonal antiserum that recognizes CFH and the CFH-related
proteins CFHR1, CFHR1α, CFHR1β, CFHR2, CFHR2α,
and CFHR5 (Figure 4). Serum-resistant B. burgdorferi LW2
bound CFH, CFHR1α, CFHR1β, CFHR2, and CFHR2α. In
contrast, wild-type strain G1 and transformant G1/pKFSS1
did not bind CFH or any CFH-related proteins. Four promi-
nent bands with apparent masses of 35, 32, 25 and 22 kDa
were detected in the last wash and the eluate fraction of
G1/pCRASP-4. Based on their mobilities, the 35 and 32 kDa
proteins most likely correspond to the two glycosylated
forms CFHR1α and CFHR1β. The 25 and 22 kDa bands were
probably the nonglycosylated and the glycosylated forms of
CFHR2. A barely visible band with an apparent molecular
mass of 55 kDa could only be detected in the eluate fraction
of G1/pCRASP-4, which was probably CFHR5. The bands
with molecular masses of 40, 60 and >250 kDa seen in the
eluate fractions of all strains represent unspecific binding of
the antiserum. There was not any indication of binding the
150 kDa CFH protein. Taken together, CRASP-4 produced on
the surface of live Borreliae strongly binds the human serum
proteins CFHR1 and CFHR2, lesser amounts CFHR5 but no
detectable CFH.
3.5. Serum Susceptibility of B. garinii Producing Surface-Local-
ized CRASP-4. To define the roles of CFHRs and CRASP-4 in
the complement resistance of Borreliae, a growth inhibition
assay was used to examine the ability of transformant G1/
pCRASP-4 to survive in the presence of complement active
NHS (Figure 5). As expected, growth of B. burgdorferi LW2
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Figure 3: Characterization of B. garinii G1 producing CRASP-4. (a) B. garinii G1 and transformed strains G1/pKFSS1 and G1/pCRASP-
4 were characterized by PCR amplification using flaB-, aadA-, and erpC-specific primers, as listed in Table 1. (b) Synthesis of CRASP-4
by transformed G1 was assessed using ligand affinity blotting. Whole cell lysates (15 μg each) of G1, G1/pKFSS1 and G1/pCRASP-4 were
separated by SDS-PAGE, and transferred to nitrocellulose. After incubation with NHS, binding of CFH to CRASP-4 was identified using a
polyclonal antiserum. A monoclonal antibody, L41 1C11, specific for the flagellin protein FlaB, was applied to show equal loading of borrelial
lysates. (c) Surface localization of CRASP-4 in transformed G1 cells. Spirochetes were incubated with or without proteinase K or trypsin,
respectively, then lysed by sonication, and total proteins were separated by SDS-PAGE. CRASP-4 was identified by ligand affinity analysis
as described above. Flagellin (FlaB) was detected with MAb L41 1C11 (dilution 1/1000) by Western blotting. (d) Demonstration of surface
expression of CRASP-4 by transformed B. garinii G1, by indirect immunofluoresecence microscopy of intact borrelial cells. Spirochetes were
incubated with rabbit polyclonal anti-ErpA/ErpC antiserum before fixation. Periplasmic FlaB, used as control, was detected by mAb L41
1C11 using fixed and unfixed cells. For counterstaining, the DNA-binding dye DAPI was used to identify all bacteria. Slides were visualized
at a magnification of ×1,000 using an Olympus CX40 fluorescence microscope mounted with a DS-5Mc charge-coupled device camera
(Nikon).
included as control was unaffected, as indicated by a contin-
uous decrease of the absorbance values (due to the colour
change of the medium). In contrast, wild-type strain G1,
G1/pKFSS1, and G1/pCRASP-4 survived in heat-inactivated
NHS but not in native NHS. The failure of the CRASP-4
producing transformant to survive suggests that binding of
CFHR1, CFHR2, and CFHR5 is not sufficient for mediating
complement resistance.
Next we examined deposition of complement activa-
tions products C3, C6 and the membrane attack complex
(MAC) on the surface of the transformant G1/pCRASP-4, B.
burgdorferi LW2, and B. garinii G1. Following incubation in
NHS, the majority of cells of G1/pCRASP-4 and wild-type
strain G1 displayed strong fluorescence, suggesting that large
amounts of C3, C6, and MAC were deposited on the borrelial
cell surface (Figure 6). In addition, extensive bleb formation,
cell fragmentation, and lack of DAPI staining indicate that
spirochetes were lysed. In contrast, bacteria incubated with
heat-inactivated NHS did not show evidence of complement
deposition (data not shown).
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Figure 5: Serum susceptibility of transformed B. garinii G1. A growth inhibition assay was used to investigate susceptibility to human serum
of B. burgdorferi strain LW2 and B. garinii strains G1 and G1/pCRASP-4. Spirochetes were incubated in either 50% NHS (open triangles)
or 50% heat-inactivated NHS (filled triangles) over a cultivation period of 9 days at 33◦C, respectively. Color changes were monitored by
measurement of the absorbance at 562/630 nm. All experiments were performed three times during which each test was done at least in
triplicate with very similar results. For clarity only data from a representative experiment are shown. Error bars represent ± SD.
Taken together, binding of CFHRs by CRASP-4 produc-
ing spirochetes does not sufficiently protect spirochetes from
complement-mediated killing.
4. Discussion
To survive in different compartments and persistently infect
their potential hosts, Borreliae have developed a variety of
strategies that include overcoming destructive attacks by
host complement. In particular, serum-resistant B. burgdor-
feri, B. afzelii, and B. spielmanii isolates bind the human
fluid phase complement regulators CFH and FHL1 that
allow spirochetes to finely regulate and inhibit complement
activation on their cell surface [6, 7, 51]. In this study,
we extend the characterization of molecular interaction of
CFH/CFHR proteins and show that the infection-associated
CRASP-4/ErpC protein of B. burgdorferi binds the host
complement regulators CFHR1, CFHR2, and CFHR5, and
to some extent CFH. However, CRASP-4 exposed to the
outer surface of viable cells preferentially binds complement
regulators CFHR1α, CFHR1β, CFHR2, and CFHR2α.
CFHR1 and CFHR5, and likely also CFHR2, exhibit com-
plement regulatory activities. Thus, recruitment of these host
proteins may help spirochetes to control complement activa-
tion. In agreement with our earlier observations of the inter-
action of CFH with native CRASP-3 and CRASP-5, the data
presented herein showed that CFHR1, CFHR2, and CFHR5
alone or in concert are not sufficient to control complement
activation at the borrelial surface. CFHR1 and CFHR2
are major constituents of serum lipoprotein particles that
also contain apolipoprotein A-I, lipopolysaccharide-binding
protein, phospholipids, and fibrinogen [52, 53]. Thus, it
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Figure 6: Deposition of complement components C3 and C6, and MAC on the surface of borrelial strains. Deposition of complement
components on B. burgdorferi LW2 (control strain), B. garinii G1 and transformant G1/pCRASP-4 were detected by indirect immuno-
fluorescence microscopy. Spirochetes were incubated with 25% NHS. Bound C3, C6, or MAC was detected using specific antibodies against
each component plus appropriate Alexa-488-conjugated secondary antibodies. For visualization of intact spirochetes, the DNA-binding dye
DAPI was used. Slides were visualized at a magnification of×1,000 and the data were recorded via a DS-5Mc CCD camera (Nikon) mounted
on an Olympus CX40 fluorescence microscope. Panels shown are representative of at least 20 microscope fields.
could be speculated that Lyme disease Borreliae capture
lipoprotein particles through CFHR1 and CFHR2 to allow
adherence to host epithelial cells and tissues, as has been
described for CFH-coated Streptococcus pneumoniae [54].
Interaction with CFH has previously been reported for
CRASP-4/ErpC and other closely related Erp proteins, for
example, OspE paralogs from B. burgdorferi, B. afzelii, B.
spielmanii, B. garinii, B. lusitaniae, B. turdi, B. tanukii, and
B. japonica [3, 6, 11, 12, 33, 35, 37, 38, 43, 51, 55–58]. Here
we demonstrate that recombinant CRASP-4 bound CFH in
ELISA or ligand affinity blot experiments using borrelial
cell lysates (Figures 2 and 3(b)). However, binding of CFH
could not be detected if CRASP-4 was coated onto magnetic
particles or was expressed on the surface of transformed
borrelial cells (Figures 1(a) and 1(b) and Figure 4). Previ-
ous studies using surface plasmon resonance revealed that
CRASP-4 in comparison to CRASP-3 and CRASP-5 displayed
strong affinity for CFHR1 and the lowest binding affinity
to CFH, suggesting a preferential binding to the smaller
CFHR molecules [38]. CRASP-3 and CRASP-5, when het-
erologously produced in B. garinii G1 or in a high-passaged
mutant strain B313 (a derivative of type strain B. burgdorferi
B31 that carries only one copy of the CRASP-5-encoding
erpA gene), similarly did not bind CFH [31, 39, P. Kraiczy
unpublished data]. However, we cannot completely exclude
conformational changes of surface-exposed CRASP-4 due to
misfolding in B. garinii. Furthermore, heterologous produc-
tion of the two CFH/FHL1-binding CRASP proteins CspA
or CspZ in B. garinii G1 did not influence their functional
activity to interact with CFH and FHL1, which might also
argue for correct folding of borrelial proteins in this model
organism [42, and P. Kraiczy unpublished data]. Conceiv-
ably, the stronger affinity of CRASP-4 to CFHR1 and CFHR2
may also favor preferential binding of these molecules to bor-
relial cells (Figure 4), even though CFH is present in a 10-fold
higher concentration in human plasma than both CFHRs
[38, 59]. As demonstrated earlier and in the present study,
the individual CFH/CFHR-binding CRASP proteins (recom-
binant or native) possess different relative affinities for CFH,
CFHR1, CFHR2, and CFHR5 [38, 39, 59]. When expressed
on borrelial surfaces, none of those CRASPs bound CFH, but
they did show prominent binding to CFHR1 and CFHR2.
Binding of CFHR5 was more pronounced for CRASP-3 as
compared to CRASP-4 and CRASP-5. Collectively, all three
CRASPs displayed the strongest affinities for CFHR2.
Apparently as a consequence of the inability of CFH
to bind to the microbial surface, bacteria accumulated des-
tructive complement activation products, that is, C3 and
MAC, on their surfaces and were killed (Figures 5 and 6).
Displacement of CFH by CFHR1 or CFHR2, which exhibits
sequence identities of 89 and 61% to the C-terminal SCRs
19 and 20 of CFH, respectively, or improper binding of CFH
to CRASP-4 by other yet unknown factors may have led to
that phenomenon. Once complement is activated, it appears
that the inhibitory activity of CFHR1 on the C5 convertase
and the capacity of CFHR5 (although bound in minuscule
amounts on the bacterial surface) to inactivate C3b can not
completely impede formation and insertion of the MAC, in
particular when large amounts of C3b and downstream effec-
tor complement components are deposited on the bacterial
membrane (Figure 6). This points to a crucial role of human
CFH and FHL1 in complement resistance of Borreliae.
A CspA-deficient B. burgdorferi strain that carries two
native copies of the erpA gene did not survive in human
serum, indicating that CRASP-5 alone cannot sufficiently
protect Lyme disease Borreliae from complement-mediated
killing [40, 41]. However, heterologous production of
CRASP-3 and CRASP-5 in the same CspA-deficient strain
significantly increased spirochetal survival in the presence of
20% human serum, suggesting that both proteins exhibit a
synergistic effect on complement resistance [43]. However,
mutant strain B313, which lacks CRASP-1, -2, and -3, but
produces native CRASP-4 and -5, did not bind CFH and was
highly susceptible to complement-mediated killing by 50%
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human serum (data not shown). Mutant strain B313 is a
clonal mutant of B31 that lacks all that strain plasmids except
cp32-1, cp32-2, cp32-3 cp32-4, cp26, and lp17 and therefore
is unable to produce a variety of outer surface proteins,
such as the major surface proteins OspA and OspB [60, 61].
The absence of a high number of outer surface proteins
might influences the entire membrane composition and,
thus, might effects the functional properties of these CFHR-
binding CRASPs in the mutant strain B313. Conceivably,
other proteins that are absent in B313 might serve as
bystanders to promote optimal binding of the large CFH pro-
tein (which forms dimeric or oligomeric complexes in solu-
tion at physiological concentrations) to CRASP-3, CRASP-4,
and CRASP-5.
Taken together, we identified complement proteins
CFHR2 and CFHR5 as novel ligands for the infection-asso-
ciated CRASP-4/ErpC protein of B. burgdorferi. CRASP-4
exposed to the borrelial surface preferentially binds CFHR1
and CFHR2 while binding of CFH and CFHR5 could only be
detected under artificial experimental conditions. Although
binding of CFHRs appears to be not necessary for comple-
ment resistance, the impact of these particular host proteins
for immune evasion and pathogenesis of Borreliae warrants
further investigations.
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“A radiation hybrid map of complement factor H and factor
H-related genes,” Immunogenetics, vol. 49, no. 6, pp. 549–552,
1999.
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Heine- Suñer, “An integrated map of the human regulator
Clinical and Developmental Immunology 11
of complement activation (RCA) gene cluster on 1q32,” Mol-
ecular Immunology, vol. 36, no. 13-14, pp. 803–808, 1999.
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